Contact Us
Drug Search Results
More Filters [+]

REGN-5837

Alternative Names: REGN-5837, REGN 5837, REGN5837
Latest Update: 2024-08-26
Latest Update Note: News Article

Product Description

REGN5837, a bispecific antibody that clusters CD22-expressing tumor cells with CD28-expressing T cells, enhances odronextamab by potentiating T cell activation and cytolytic function. REGN5837 monotherapy shows limited activity and no toxicity in primate studies, it augments T cell activation when dosed in combination with odronextamab. (Sourced from: https://investor.regeneron.com/static-files/3f2c8835-1da3-43e6-a50d-7080d8d935ab)

Mechanisms of Action: CD22 Inhibitor,CD28 Inhibitor

Novel Mechanism: Yes

Modality: Bispecific Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for REGN-5837

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ATHENA-1

P1

Recruiting

Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

2027-06-02

Recent News Events

Date

Type

Title

08/26/2024

News Article

 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

06/28/2024

News Article

 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions